MyBlueDots

NATICK, Mass.–(BUSINESS WIRE)–Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced topline results from the AUDACITY Food & Drug Administration (FDA) pivotal trial evaluating the safety and efficacy of the Allurion Balloon. The AUDACITY trial is an open-label, multicenter, randomized, controlled study and is the first FDA pivotal trial on an intragastric balloon for weight loss to report primary outcomes beyond 9 months. 550 subjects were random

SAN DIEGO & BERLIN & DURHAM, N.C.–(BUSINESS WIRE)–Vividion Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets and develop small molecule precision therapeutics for devastating cancers and immune disorders, today announced the acquisition of Tavros Therapeutics, Inc., a precision oncology platform company. Vividion is a wholly owned and independently operating subsidiary of Bayer AG. The

AUSTIN, Texas–(BUSINESS WIRE)– #JPM2025–Gameto to Present at 43rd Annual J.P. Morgan Healthcare Conference

VANCOUVER, British Columbia–(BUSINESS WIRE)– #biotech–Aspect Biosystems secures $115M Series B to advance bioprinted tissue therapeutics, accelerating development of functional cures for serious diseases

SAN FRANCISCO–(BUSINESS WIRE)–Tonal, the pioneer of the world’s smartest strength training system, today unveiled Tonal 2, the latest iteration of its breakthrough at-home fitness solution. Updated from the inside out, Tonal 2 features an all-black design with sleek chrome accents that seamlessly complement any living space, along with hardware advancements and greater durability that level up the toughest workouts. Beyond its striking new look, Tonal 2 introduces cutting-edge workout feature

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer and infectious diseases, today announced a clinical trial collaboration and supply agreement with Amgen (NASDAQ:AMGN) to evaluate etakafusp alfa (formerly known as AB248), Asher Bio’s investigational CD8+ T cell targeted interleukin-2 (IL-2) immunotherapy, in combination with IMDELLTRA® (tarlatamab), Amgen’s DLL3-targeting Bispecific T-cell Engage

MIAMI–(BUSINESS WIRE)–Ontrak, Inc (NASDAQ: OTRK), (“Ontrak” or the “Company”), an AI-powered and telehealth-enabled behavioral healthcare company, announced it has signed an agreement to provide its behavioral health solutions to Intermountain Health’s Medicare Advantage members in Nevada. Intermountain Health is a prominent healthcare system operating 400 clinics and 34 hospitals in the western United States. Intermountain Health is known for its high quality, affordable and personalized car

BOSTON–(BUSINESS WIRE)–AI Proteins, Inc., a biotechnology company that utilizes computational de novo protein design to create therapeutic miniproteins, announced today it has entered into a Collaborative Research Agreement with the University of Missouri-Columbia to work with Dr. Carolyn Anderson, Simón-Ellebracht Professor in Medicinal Chemistry and Professor of Radiology, and her team to jointly pursue specific research projects to advance the use of de novo designed miniproteins for targe

PEKÍN, ALAMEDA (California) y TAIPÉI–(BUSINESS WIRE)–Biocytogen (HKEX: 02315) y Acepodia (6976:TT) anunciaron hoy una alianza estratégica para evaluar de forma conjunta un programa de conjugados de anticuerpos-fármacos biespecíficos de carga doble (BsAD2C). Esta colaboración combina la plataforma RenLite® de Biocytogen con la tecnología de conjugación anticuerpo-fármaco doble (AD2C) de Acepodia para enfrentar algunos de los desafíos oncológicos más difíciles, como la heterogeneidad y la resis

SAN FRANCISCO–(BUSINESS WIRE)–Vir Biotechnology, Inc. (Nasdaq: VIR) today is presenting initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, targeting a variety of HER2-expressing solid tumors; and VIR-5500, targeting PSMA in metastatic castration-resistant prostate cancer (mCRPC). Data show encouraging preliminary safety and efficacy profiles with no dose-limiting cytokine release syndrome (CRS), maximum tolerated dose (MTD) not yet reached as dose escalation co